期刊簡介預計審稿時間： 10 Weeks

Molecular Biomedicine, launched in 2020, is a peer-reviewed, open access journal published annually. It is a collaborative venture between the globally renowned scientific publishing company Springer Nature and the Sichuan Association for the Promotion of International Medical Exchange. This journal is dedicated to publishing high-quality research in the field of biomedicine from a molecular perspective, encompassing both fundamental and clinical studies.

Focusing on the mechanisms of human disease, as well as advancements in prevention, diagnosis, and treatment, Molecular Biomedicine aims to become a leading international academic journal with a significant impact in the biomedicine sector. The journal's commitment to open access ensures that its content is widely accessible, fostering global exchange of scientific knowledge and accelerating the dissemination of breakthroughs in molecular medicine.By embracing innovative research methodologies and interdisciplinary approaches, Molecular Biomedicine is positioned to contribute to the advancement of medical science, offering insights that could potentially lead to improved healthcare outcomes. The journal's editorial board, composed of experts from around the world, ensures that the published work meets the highest standards of scientific rigor and integrity, solidifying its reputation as a trusted source of information in the scientific community.

《分子生物醫學》于2020年創刊，是一本同行評審、每年出版一卷的開放獲取期刊。這是全球知名的科學出版公司Springer Nature與四川省國際醫學交流促進會合作創立的。該期刊致力于發表從分子角度出發的高質量生物醫學研究，包括基礎和臨床研究。專注于人類疾病的機制，以及在預防、診斷和治療方面的進展，雜志旨在成為在生物醫學領域具有重要國際影響力的學術期刊。期刊對開放獲取的承諾確保了其內容的廣泛可及性，促進了科學知識的全球交流，并加速了分子醫學突破的傳播。

通過采用創新的研究方法和跨學科的方法，雜志有望為醫學科學的進步做出貢獻，提供可能帶來改善醫療結果的洞察。由世界各地的專家組成的期刊編委會確保發表的工作達到最高的科學嚴謹性和誠信標準，鞏固了其作為科學界值得信賴的信息來源的聲譽。

如果您需要協助投稿或潤稿服務，您可以咨詢我們的客服老師。我們專注于期刊咨詢服務十年，熟悉發表政策，可為您提供一對一投稿指導，避免您在投稿時頻繁碰壁，節省您的寶貴時間，有效提升發表機率，確保SCI檢索（檢索不了全額退款）。我們視信譽為生命，多方面確保文章安全保密，在任何情況下都不會泄露您的個人信息或稿件內容。